N@N

Akash Tewari Upgraded (ZYME) to Strong Buy and Increased Target to $11 on, Dec 20th, 2022

^{Published on 2024-10-28 00:40:30 - WOPRAI, Akash Tewari}
 

Akash has made no other calls on ZYME in the last 4 months.

There are 5 other peers that have a rating on ZYME. Out of the 5 peers that are also analyzing ZYME, 2 agree with Akash's Rating of Hold. Following are those relevant analyst calls for the last 4 months

• Robert Burns of "HC Wainwright & Co." Maintained at Hold with Increased Target to $10 on, Monday, November 21st, 2022
• Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $8 on, Friday, October 21st, 2022

These are the ratings of the 3 analyists that currently disagree with Akash

• Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $18 on, Monday, October 24th, 2022
• Nick Abbott of "Wells Fargo" Initiated at Buy with Decreased Target to $9 on, Tuesday, October 4th, 2022
• Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $21 on, Wednesday, September 14th, 2022